Aesthetics Product Guide

Allergan Gets Approval For JUVÉDERM

Jim Marino — Tue, 02 Feb 2010 05:08:34 +0000

Allergan, the pharmaceutical company which manufactures Botox, has received the approval from the US Food and Drug Administration’s (FDA) for its JUVÉDERM® XC. JUVÉDERM XC is a new formulation that contains lidocaine to make the treatment of moderate to severe facial wrinkles and folds much more comfortable.

First U.S. Face Transplant Reported In “Plastic And Reconstructive Surgery”

Jim Marino — Mon, 25 Jan 2010 06:39:32 +0000

Detailed information on the first facial transplantation procedure performed in the United States is presented in the January issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The patient has recovered well, with no serious complications through eight months of follow-up. With “true dedication” to her recovery, the patient has regained most facial functions, and the ability to eat solid foods and drink from a cup.

For the full story, Click Here

How Sunlight Causes Skin Cells To Turn Cancerous

Jim Marino — Mon, 18 Jan 2010 15:33:34 +0000

A new study by Loyola University Health System researchers could lead to alternative treatments that would shrink skin cancer tumors with drugs. The drugs would work by turning on a gene that prevents skin cells from becoming cancerous. More than 1 million people in the United States are diagnosed with skin cancer each year. In the new study, researchers examined a type of skin cancer, called squamous cell carcinoma.

For the full story, Click Here

Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma

Jim Marino — Tue, 12 Jan 2010 05:54:31 +0000

Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for its worldwide commercialization.

For the full story, Click Here

Endoscopic Sinus Surgery Improves Quality Of Life For Chronic Sinusitis Patients

Jim Marino — Mon, 04 Jan 2010 10:47:48 +0000

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology – Head and Neck Surgery. CRS is a debilitating form of sinusitis that can lead to significant physical symptoms as well as substantial functional and emotional impairment.

For the full story, Click Here

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) and ExcellagenFX(TM)

Jim Marino — Mon, 28 Dec 2009 07:02:35 +0000

Cardium Therapeutic has announced that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket notification filing with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its Excellagen(TM) product candidate based on positive data from the Company’s recently completed Phase 2b Matrix clinical study. ExcellagenXL(TM) and ExcellagenFX(TM) are advanced wound care management medical devices comprising customized collagen protein-based topical gels designed for use by health care professionals for patients with dermal wounds.

The the full story, Click Here

Plastic Surgeons Often Go Under the Knife, Survey Shows

Jim Marino — Mon, 21 Dec 2009 11:20:50 +0000

The American Society of Plastic Surgeons surveyed 276 of its members and found that 62 percent of them had undergone at least one cosmetic procedure. This most often included Botox injections and chemical peels. Also, a third of these doctors had undergone an actual invasive surgery, with liposuction being the most common procedure. Many of the surgeons in the survey were women.

For the full story, Click Here

New non-invasive skin tightening procedure

Jim Marino — Mon, 14 Dec 2009 12:34:24 +0000

The Department of Dermatology at the University of Alabama at Birmingham (UAB) is now offering a new non-invasive skin tightening procedure. The skin is tightened by the use of a device called Thermage that uses radio waves. Thermage treatments are done without anaesthesia and can be completed in one or two sessions in time ranging from 20 minutes to over an hour. Thermage treatment warms the skin, which absorbs radiofrequency energy to tighten the collagen.

Epic Wound Care Signs Distribution Agreement With Coreva Health Science, LLC

Jim Marino — Mon, 07 Dec 2009 15:16:45 +0000

United EcoEnergy Corp. has announced that its wholly-owned portfolio company, Epic Wound Care, Inc. has signed an international distribution agreement with Coreva Health Science LLC (Coreva) to distribute Epic’s Hemostyp(TM), under the private label ActCel. Hemostyp is an innovative gauze product designed for use on any wound where bleeding is still present. Upon contact with moisture, the gauze forms a gel-like substance that acts as a homeostatic agent to stop the bleeding quickly.

New Anti-Aging iPhone App Promises Better Skin

Jim Marino — Mon, 30 Nov 2009 12:26:18 +0000

United Holdings Group has created 11 apps, available on the iTunes App Store the first week of January 2010, that claim to help with the anti-aging process. The main one will have 10 Color-Light and Sound Therapy treatments to deal with wrinkles, acne, cellulite, joint pain, sleep disorder and hair growth stimulation. The healing strategy purports to use wavelengths of light and sound to stimulate cells to produce collagen and elastin, resulting in firmer skin.